Aimovig® gains US FDA approval for the preventive treatment of migraine

Written by Sharon Salt, Editor

Novartis (Basel, Switzerland) and Amgen (CA, USA) have announced that the US FDA has approved Aimovig® (erenumab) for the preventive treatment of migraine in adults. Aimovig is a novel therapeutic approach as the first and only FDA-approved treatment specifically developed to prevent migraine by blocking the calcitonin gene-related peptide receptor (CGRP-R), which is believed to play a critical role in migraine. “Aimovig is the first therapy of its kind targeting the CGRP receptor, and has demonstrated robust efficacy across the spectrum of migraine. We look forward to working closely with Amgen in the US to bring this treatment to physicians...

To view this content, please register now for access

It's completely free